Brown Advisory Inc. Has $44.72 Million Stake in SiBone (NASDAQ:SIBN)

Brown Advisory Inc. cut its stake in shares of SiBone (NASDAQ:SIBN - Free Report) by 12.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,187,398 shares of the company's stock after selling 453,047 shares during the period. Brown Advisory Inc. owned approximately 7.51% of SiBone worth $44,719,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SIBN. Virtus Fund Advisers LLC acquired a new stake in shares of SiBone during the fourth quarter worth $40,000. GAMMA Investing LLC raised its position in shares of SiBone by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after purchasing an additional 3,867 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of SiBone during the fourth quarter worth $97,000. Johnson Investment Counsel Inc. acquired a new stake in shares of SiBone during the first quarter worth $148,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of SiBone during the fourth quarter worth $155,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SiBone Stock Down 8.4%

NASDAQ:SIBN traded down $1.58 during trading hours on Friday, hitting $17.20. 382,421 shares of the company's stock traded hands, compared to its average volume of 393,559. The firm has a market cap of $733.06 million, a P/E ratio of -26.88 and a beta of 0.93. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. The stock's fifty day moving average price is $18.17 and its two-hundred day moving average price is $16.29.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. On average, research analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Truist Financial upped their price target on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th.

Insider Buying and Selling

In other SiBone news, CFO Anshul Maheshwari sold 9,585 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $19.76, for a total value of $189,399.60. Following the transaction, the chief financial officer directly owned 224,507 shares of the company's stock, valued at $4,436,258.32. This represents a 4.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the completion of the transaction, the chief executive officer directly owned 302,958 shares in the company, valued at approximately $5,204,818.44. The trade was a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 101,702 shares of company stock worth $1,866,404. Insiders own 4.00% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.